FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
15 letters match. Newest first.
-
DrugsUSV Private Limited
FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.
High risk -
DrugsRohto Pharmaceutical Co., Ltd.
FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.
High risk -
DevicesMeridian Bioscience, Inc
FDA warns Meridian Bioscience's Magellan Diagnostics over quality system failures and unreported problems with its blood lead test kits.
High risk -
DrugsWinder Laboratories, LLC
FDA warns Winder Laboratories of adulterated prescription drugs due to cleaning and facility failures.
High risk -
DrugsRhyz Analytical Labs
FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.
High risk -
DrugsSiddha Flower Essences, LLC., dba Siddha Remedies
FDA cites Siddha Remedies, a maker of children's homeopathic drugs, for untested water and botanicals and microbial contamination.
High risk -
DrugsDaewoo Pharmaceutical Co., Ltd.
FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.
High risk -
DrugsLibby Laboratories, Inc.
FDA warned Libby Laboratories of Berkeley, California, that its drug manufacturing violated CGMP, including releasing a hospital antiseptic without microbial testing.
High risk -
DrugsLaboratoire Druide Inc.
FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.
High risk -
DevicesCriticare Technologies, Inc.
FDA warns Criticare Technologies over patient monitors after finding unresolved CAPAs, weak design controls and supplier checks at its Warwick, Rhode Island plant.
High risk -
DrugsCentral Admixture Pharmacy Services, Inc.
FDA warned sterile drug compounder Central Admixture Pharmacy Services (Phoenix) that dirty areas and weak sterility testing made its drugs adulterated.
High risk -
DrugsSun Pharmaceutical Industries Ltd.
FDA warns Sun Pharmaceutical over CGMP violations in sterile injectable manufacturing at its Halol, India facility.
High risk -
DrugsGTP International Corp
GTP International, a Mesquite, TX maker of OTC hand sanitizer, refused FDA's repeated requests for manufacturing records.
Medium -
DrugsNanomateriales QuĂmicos Avanzados, S.A. de C.V.
FDA found Mexican maker Nanomateriales' ZANILAST hand sanitizer labeled 65% ethanol contained 1-propanol, with quality and labeling violations.
High risk -
DrugsBotanicals Internacional S.A. de C.V.
Botanicals Internacional's inatek hand sanitizer was found to contain methanol instead of labeled ethanol and was refused at U.S. border.
High risk